Brown, chief fellow in the division of hematology and oncology at Penn Medicine, said the small, descriptive study, which evaluated 42 patients and was presented as part of a poster session at ASCO Annual Meeting, found that chemotherapy does retain some activity for this patient population. Read more . . .
In this video, Timothy Brown, MD, discussed the results of his study on treatment outcomes of patients with platinum-sensitive BRCA or PALB2-mutated pancreatic cancer who have been treated with and progressed on rucaparib.